hydroxyproline has been researched along with fr 167653 in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Arai, T; Fujiwara, H; Goya, S; Hayashi, S; Kida, H; Matsuoka, H; Mori, M; Morishita, H; Osaki, T; Tachibana, I | 1 |
1 other study(ies) available for hydroxyproline and fr 167653
Article | Year |
---|---|
A p38 MAPK inhibitor, FR-167653, ameliorates murine bleomycin-induced pulmonary fibrosis.
Topics: Activating Transcription Factor 2; Animals; Antibiotics, Antineoplastic; Bleomycin; Bronchoalveolar Lavage Fluid; Connective Tissue Growth Factor; Cyclic AMP Response Element-Binding Protein; Disease Models, Animal; Gene Expression; Growth Inhibitors; Growth Substances; Hydroxyproline; Immediate-Early Proteins; In Situ Nick-End Labeling; Injections, Intravenous; Intercellular Signaling Peptides and Proteins; Lung; Male; Mice; Mice, Inbred ICR; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pulmonary Fibrosis; Pyrazoles; Pyridines; RNA, Messenger; Transcription Factors; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha; Weight Gain | 2002 |